Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin in Japanese Pediatric Participants with cSSTI or Bacteremia
NCT03643952Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of daptomycin in skin and soft tissue infection (SSTI), Bacteremia, sponsored by Merck & Co.. Started Dec 2018; status: completed.
02
Drugs
daptomycin
03
Conditions
skin and soft tissue infection (SSTI)Bacteremia
Beyond the preview
Go deeper on NCT03643952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643952.